Access Statistics for Aidan Hollis

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A Contractual Approach to the Gray Market 0 1 1 427 0 2 3 2,102
Complementarity, Competition and Institutional Development: The Irish Loan Funds through Three Centuries 0 0 1 295 0 2 6 1,322
Exclusivity Restrictions in Markets with Adverse Selection: The Case of Extended Warranties 0 0 0 106 0 0 0 842
Generic drug pricing in Canada: components of the value-chain 0 0 4 106 0 0 5 328
Microcredit in Pre-Famine Ireland 1 1 1 336 1 1 9 1,771
New Approaches to Rewarding Pharmaceutical Innovation 0 0 0 94 0 1 1 166
Privacy, Driving Data and Automobile Insurance: An Economic Analysis 0 0 0 70 0 1 3 246
Privacy, Driving Data and Automobile Insurance: An Economic Analysis 0 0 0 0 0 0 3 282
Subsidizing the Competition 0 0 0 134 0 0 0 682
The Evolution of A Microcredit Institution: The Irish Loan Funds, 1720 - 1920 0 0 1 324 1 2 6 1,591
Total Working Papers 1 2 8 1,892 2 9 36 9,332


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A National Formulary for Canada 0 1 1 547 0 1 2 4,112
A contractual approach to the gray market 0 0 0 123 0 2 7 409
An Optional Delinked Reward System: Making Pharmaceutical Innovation Work for Everyone 0 0 0 0 1 2 5 6
Climate impact auctions: an underused tool for green subsidies in the Global South 0 0 0 0 0 1 1 1
Co-authorship and the output of academic economists 0 0 0 72 0 2 3 251
Competition policy in open economies 0 0 0 32 0 0 2 168
Der Green Impact Fund for Technology 0 0 1 3 1 2 7 16
Generic Drug Pricing and Procurement: A Policy for Alberta 0 0 0 4 0 0 0 18
Governance of electricity transmission systems 0 0 0 81 0 0 1 213
How do Brands’ “Own Generics” Affect Pharmaceutical Prices? 0 0 1 191 1 2 4 488
How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada? 0 0 0 2 0 1 1 15
Industrial Concentration, Output, and Trade: An Empirical Exploration 0 0 0 37 0 0 0 104
Making Sure Orphan Drugs Don’t Get Left Behind 0 0 0 3 0 0 3 20
Microcredit in Prefamine Ireland 0 0 1 62 0 1 4 269
Microcredit: What can we learn from the past? 0 0 2 328 0 0 8 971
Microfinance and Famine: The Irish Loan Funds during the Great Famine 0 0 1 98 1 2 5 443
Newton's First Law as Applied to Pharmacies: Why Entry Order Matters for Generics 0 0 2 32 0 0 5 120
Patient income and health innovation 0 0 0 11 0 3 3 41
Predicting patent challenges for small-molecule drugs: A cross-sectional study 0 0 0 0 0 0 1 1
Preliminary Injunctions and Damage Rules in Patent Law 0 0 0 72 0 1 1 332
Price‐cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals 0 0 0 9 0 1 1 35
Strategic Implications of Learning by Doing 0 0 0 87 0 0 0 561
Sustainable Financing of Innovative Therapies: A Review of Approaches 0 0 1 15 0 1 6 42
The Anti-Competitive Effects of Brand-Controlled "Pseudo- Generics" in the Canadian Pharmaceutical Market 0 0 0 233 0 0 3 730
The Role of Local Depositors in Controlling Expenses in Small‐Scale Financial Intermediation: An Empirical Analysis 0 0 0 16 0 1 1 84
The economic theory of cost‐effectiveness thresholds in health: Domestic and international implications 0 0 0 2 1 1 3 14
The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis 0 0 0 0 0 0 0 1
The importance of being first: evidence from Canadian generic pharmaceuticals 0 1 5 308 0 1 7 718
The large-scale integration of wind generation: Impacts on price, reliability and dispatchable conventional suppliers 0 0 0 60 0 0 5 163
The life-cycle of a microfinance institution: the Irish loan funds 0 0 1 157 0 2 4 459
The path of least resistance: Paying for antibiotics in non-human uses 0 0 0 6 0 0 1 33
Total Journal Articles 0 2 16 2,591 5 27 94 10,838


Statistics updated 2025-10-06